Allogene Therapeutics (NASDAQ:ALLO) Price Target Raised to $10.00

Chronological Source Flow
Back

AI Fusion Summary

Jefferies lifted Allogene Therapeutics’ target to $10, buy; Canaccord Genuity kept buy with $14. Pegasystems: Citigroup cut target to $70, buy; KeyCorp set $60; Zacks strong‑buy; Citizens Jmp lowered to $58, outperform.
16/04 08:34 defenseworld.net
3 Πηγές
16/04 09:53 defenseworld.net
16/04 11:20 defenseworld.net
Comments
Loading...
0